✦ LIBER ✦

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

✍ Scribed by Nadeem A. Sheikh, Daniel Petrylak, Philip W. Kantoff, Corazon dela Rosa, Frances P. Stewart, Ling-Yu Kuan, James B. Whitmore, James B. Trager, Christian H. Poehlein, Mark W. Frohlich, David L. Urdal

Book ID: 118781421
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 561 KB
Volume: 62
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-012-1317-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Denosumab and bone-metastasis-free survi

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

✍ Matthew R Smith; Fred Saad; Robert Coleman; Neal Shore; Karim Fizazi; Bertrand T 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 216 KB

Re: Denosumab and Bone-Metastasis-Free S

Re: Denosumab and Bone-Metastasis-Free Survival in Men With Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial

✍ Walsh, Patrick C. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 115 KB

Overall Survival Benefit of Radium-223 C

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

✍ C. Parker; D. Heinrich; J.M. O'Sullivan; S. Fossa; A. Chodacki; T. Demkow; A. Cr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

115 - Immediate hormonotherapy with an L

115 - Immediate hormonotherapy with an LHRH analogue improves local control and survival in patients with locally advanced prostate cancer treated by radiotherapy. A randomized phase III clinical trial of the EORTC

✍ M. Bolla; D. Gonzalez; P. Warde; J.B. Dubois; R. Mirimanoff; G. Storme; J. Berni 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Final safety and efficacy analysis of th

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial

✍ Nicholas D. James; Armelle Caty; Heather Payne; Michael Borre; Bernard A. Zonnen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB

Commentary on “Denosumab and bone-metast

Commentary on “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomized, placebo-controlled trial.” M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damião, T.L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gómez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, C. Goessl, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

✍ Trump, Donald L. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 72 KB